ERBB2 and neoplasm: Triple-negative breast cancer (TNBC), characterised by the lack of HR and HER2 expression [1], most likely benefits from immune checkpoint inhibitors (ICIs) because tumour-infiltrating lymphocytes (TILs) and tumour mutation burden are higher in TNBC than in other subtypes [2, 3].